4BIO Capital

We are delighted to share that our portfolio company, Vianautis, has entered a collaboration agreement with Eli Lilly and Company.   This partnership will develop further ViaNautis’ PolyNaut® platform, a versatile nanomedicine technology directing intracellular delivery of therapeutic modalities, assisted by GOTO® technology.   #4BIO #ViaNautis #Lilly #Biotech #collaboration #polyNaut 

We are excited to share that we have led a $28.4 million Series A Financing round of March Biosciences: https://lnkd.in/gGf-EXH3   This fundraise will allow March Bio to further develop its rapidly progressing CAR-T therapy, MB-105, for the treatment of relapsed and refractory CD5+ T-cell Lymphoma. The candidate drug has shown promising Phase 1 results, and the proceeds from 4BIO will support the transition to Phase 2 clinical trials in early 2025.  #4BIO #VC #MarchBio #Biotech #Fundraise

Congratulations to our portfolio company Vianautis on the appointment of Adi Hoess as Chief Executive Officer.   Dr Hoess has significant biotech leadership experience, and we look forward to the important role he will play in the development and growth of ViaNautis as they progress the polyNaut® platform to create genetic medicines of the future.   #AdvancedTherapies #Nanomedicines #DrugDelivery #VC #CEO #Appointment

Last week, we enjoyed hosting our Annual Conference and AGM at The Royal Institution in London.   The day was filled with insightful panel discussions and fireside chats with leading business and technical experts in the advanced therapies field, including from some of our portfolio companies Araris Biotech AG, SparingVision, Ray Therapeutics, Inc., Trogenix and Vianautis.   A big thank you to Philippe Fauchet and Abbas Hussain for moderating the fireside chats and to everyone who participated and attended, including Ascend Advanced Therapies, Entact Bio and Hornet Therapeutics!   #4BIO #VC #AdvancedTherapies #GeneTherapy #AGM #Conference #Networking

Big congratulations to our Advisor Abbas Hussain who has joined Moderna’s Board of Directors.   Abbas has more than 35 years of commercial leadership and operating experience in healthcare, having most recently served as CEO at Vifor Pharma.   His significant sector expertise is a real asset to 4BIO Capital and we wish him every success in his new appointment at Moderna.   Read about Abbas’ appointment in full here - https://lnkd.in/gApv9j3T   #4BIO #VC #AdvancedTherapies #GeneTherapy #Appointments

On Wednesday and Thursday this week, Managing Partner, Andrew Kozlov and investment analyst Alexander M. , will be in Basel for the 24th Annual Biotech in Europe Forum. If you would like to set up a meeting with them, please email info@4biocapital.com.   The event will bring together biotech leaders, investors, and researchers from across the globe, providing interesting insights in advanced therapies and prospects for 2025.   To find out more: About the 24th Biotech in Europe Forum (sachsforum.com)   #4BIO #Sachs_BEF #Networking #VC

Dmitry 'Dima' Kuzmin recently spoke with Nick Herbert from Investors in Healthcare. During the discussion, Dima shared exclusive insights into the mission and strategy driving 4BIO Capital: https://lnkd.in/e8eZaHkY The interview covered an array of topics, including 4BIO’s internal investment strategy and Dima’s thoughts on the external funding environment. Dima reflected on how his personal background was influential in the creation of 4BIO and the Company’s decision to invest solely in the advanced therapies sector. Check out the full interview to learn more about 4BIO’s vision and the exciting developments in the world of healthcare venture capital. #4BIO #VC #AdvancedTherapies #GeneTherapy #Innovation #interview

Dmitry 'Dima' Kuzmin, Managing Partner, recently shared his thoughts on the Cell and Gene Therapy space, in an interview with Cell & Gene Therapy Insights (BioInsights): https://lnkd.in/e-q2GHrE Dima spoke about the current landscape of advanced therapies in Europe, highlighting both the progress and the challenges currently being faced. He discussed the importance of developing robust manufacturing capabilities, especially for complex gene and RNA therapies, and how collaboration across the industry is essential for success. Dima touched on the critical need for innovative approaches to regulatory and reimbursement pathways, ensuring that groundbreaking therapies can reach patients faster and more efficiently. #4BIO #VC #AdvancedTherapies #GeneTherapy #Innovation #interview

Dmitry 'Dima' Kuzmin, Managing Partner, recently spoke with Jim Cornall on Labiotech.eu’s latest ‘Beyond Biotech’ podcast episode about the European biotech status quo.   They discussed the strength of gene therapy start-ups in the UK due to its strong heritage and experienced talent pool, the need for increased cohesion and reduced friction in the industry globally and the requirement to reduce costs and increase efficiency in therapy development and distribution.   Listen to the full podcast here: https://lnkd.in/emvxDCD4   #4BIO #VC #AdvancedTherapies #biotech #podcast

Dmitry 'Dima' Kuzmin, Managing Partner at 4BIO, spoke to Ayisha Sharma at Endpoints News about what the new UK government policies could mean for life sciences.   Dima highlighted that the UK does not have enough venture funds to support the number of biotech companies it has but by using creative solutions such as fund of funds, pension funds could increase investment in UK biotech’s.      Read the full article here: https://lnkd.in/ejZwjjF4   #4BIO #VC #AdvancedTherapies #biotech